ERBB2 and breast cancer: This dual antagonist also enhanced the efficacy of ado-tratuzumab emtansine against brain metastasis from HER2-positive BC cells [155], and macitentan sensitized experimental BC (MDA-MB-231) brain metastases to paclitaxel in mice [156].